ZTlido Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians who prescribe ZTlido (lidocaine topical system 1.8%) to patients with post-herpetic neuralgia (PHN), 2025-2026 has brought a shifting landscape: the first generic approval, evolving formulary restrictions, and patient reports of inconsistent pharmacy availability. This guide provides an evidence-based overview of what's happening and how to navigate it for your patients.

Current Availability Status: Not a Formal Shortage, But Access Is Uneven

As of 2026, ZTlido does not appear on the FDA Drug Shortage Database. Scilex Pharmaceuticals continues to manufacture and distribute the product. However, clinicians are receiving reports from patients who cannot locate ZTlido at their local pharmacy. This pattern is consistent with localized supply disruptions rather than a systemic national shortage — a distinction that matters for how you counsel patients and document prescribing decisions.

Key Market Development: Generic Approval in March 2025

The FDA approved the first generic lidocaine 1.8% topical system on March 26, 2025, manufactured by Aveva Drug Delivery Systems (a DifGen company). This bioequivalent generic was approved as therapeutically equivalent to ZTlido. However, commercial launch has been delayed by ongoing patent litigation — Scilex appealed the district court's non-infringement ruling to the Federal Circuit in March 2025.

Clinical implications:

The generic is bioequivalent — one 1.8% generic patch = one brand ZTlido patch in terms of lidocaine exposure

If the generic launches in your area, it can be substituted at the pharmacy level without a new prescription

If you prefer the brand (e.g., due to adhesion differences), document your DAW (Dispense As Written) preference

Formulary and Insurance Considerations in 2026

ZTlido faces significant formulary access challenges across commercial and government payers:

Tier placement: ZTlido is typically Tier 2-3 on commercial formularies; some plans require non-preferred brand prior authorization

Prior authorization: Many payers require PA for ZTlido, citing availability of generic lidocaine 5% patches as a lower-cost alternative

Step therapy: Several payers (including some Medicare Part D plans and Medicaid programs) require a trial of generic lidocaine 5% patches before ZTlido is covered

Quantity limits: Many plans limit ZTlido to 90 patches per 30 days (equivalent to 3 patches/day), consistent with labeled dosing

Medicare coverage: ZTlido requires Part D coverage; it is not covered under Part B. Some Medicare Advantage plans have restricted formulary access.

PA Documentation: Making the Case for ZTlido

When submitting a prior authorization for ZTlido, consider including the following clinical rationale:

Documented PHN diagnosis with duration and severity (pain scores, functional impact)

Trials of and inadequate response or intolerance to generic lidocaine 5% patches (adhesion failure, inadequate pain control, skin reactions)

Clinical advantage of ZTlido: superior adhesion documented in studies vs. generic patches

Safety advantage: lower residual lidocaine content reduces risk to household members (children, pets)

Non-opioid necessity: document if opioid-sparing is a clinical goal for this patient

Clinical Evidence Base for ZTlido

ZTlido's clinical evidence includes:

Bioequivalence: A crossover PK study in 53 healthy volunteers confirmed equivalent AUC and Cmax to Lidoderm 5%

Adhesion superiority: Open-label studies demonstrate improved adhesion vs. Lidoderm and multiple generic 5% patches

Safety with heat/exercise: PK data confirm safe use during moderate exercise (cycling 30 min) and short water exposure (10-min shower)

AAPM guidelines: The American Academy of Pain Medicine (2023) cites high evidence and strong consensus for lidocaine topical systems (including ZTlido) for PHN

Therapeutic Alternatives When ZTlido Is Inaccessible

If a patient cannot access ZTlido, the evidence-supported alternatives for PHN include:

Lidocaine 5% patch (generic): Therapeutically equivalent lidocaine delivery; lower cost; broader pharmacy availability

Gabapentin: First-line oral option; FDA-approved for PHN; widely available and inexpensive as generic

Pregabalin: Second oral option; FDA-approved; Schedule V; more predictable pharmacokinetics than gabapentin

Capsaicin 8% (Qutenza): In-clinic application; proven efficacy for PHN; duration of effect up to 3 months

Tricyclic antidepressants: Off-label; amitriptyline or nortriptyline at low doses; NNT ~2.6 for PHN; use with caution in elderly

How medfinder Can Help Your Patients Access ZTlido

When patients contact your office saying they can't find ZTlido, consider directing them to medfinder. medfinder is a paid service that calls pharmacies near the patient to find which ones have ZTlido in stock, then texts the patient results. This reduces callbacks to your office from patients unable to fill their prescription and helps your patients stay on their prescribed therapy.